Anti-IL-17 antibody also preserves skeletal loss in osteoporosis by enhancing osteoblastic bone formation and suppressing osteoclastic bone resorption, as well as protecting against IL-17-mediated immune damages [48]. Here, IL17A is linked to osteoporosis.